gene therapy

REGENXBIO faces class action lawsuit over RGX-111 gene therapy trial disclosures. Lead plaintiff deadline is April 14, 2026.

uniQure's $QURE stock crashes 49% after FDA rejects Huntington's gene therapy approval pathway; securities fraud lawsuit filed alleging misleading statements about regulatory expectations.

Class action lawsuits filed against PayPal for misleading revenue projections and REGENXBIO for concealing gene therapy safety concerns, both triggering significant stock declines.

REGENXBIO faces securities lawsuit alleging misleading statements about RGX-111 gene therapy. Lead plaintiff deadline extended to April 14, 2026.

Vertex Pharmaceuticals outperforms Centessa with profitable cystic fibrosis revenue, successful product launches, and advanced pipeline, offering lower-risk investment profile versus pre-revenue competitor.

Rep. Tim Moore extends small-cap stock strategy into 2026 after achieving 52% portfolio gains in 2025, significantly outpacing the S&P 500.

REGENXBIO faces class action lawsuit alleging false statements about gene therapy RGX-111's safety and efficacy. Investors must act by April 14, 2026 deadline.

REGENXBIO faces class action lawsuit alleging executives made false statements about RGX-111 gene therapy's efficacy and safety, seeking shareholder damages.

Class action lawsuit filed against REGENXBIO for allegedly making false statements about gene therapy safety and efficacy while withholding adverse trial information from investors.

CRISPR Therapeutics gains FDA approval for Casgevy, its first gene-editing therapy for rare blood disorders, validating the platform with multiple pipeline candidates in development.

REGENXBIO faces securities class action alleging false statements about RGX-111 gene therapy program and clinical trial outcomes. Investors from February 2022-January 2026 may recover damages.

4DMT will present pipeline progress at three major healthcare conferences in March 2026, showcasing late-stage programs including 4D-150 for retinal disease and 4D-710 for cystic fibrosis.

ALS therapeutics market to more than double by 2035, reaching $1.96 billion. Growth driven by genetic therapies, improved diagnostics, and disease awareness.

REGENXBIO faces class action lawsuit over allegedly false safety disclosures for gene therapy RGX-111. FDA clinical hold triggered 17.8% stock drop after adverse trial findings.

REGENXBIO faces securities lawsuit over alleged false statements about gene therapy safety. Investors have until April 14 deadline to join class action after FDA clinical hold.

REGENXBIO faces class action lawsuit alleging false statements about RGX-111 gene therapy trial results, covering securities purchased between February 2022 and January 2026.

Securities lawsuit against uniQure alleges misleading FDA disclosure statements about gene therapy candidate AMT-130. Stock fell 49% after November FDA feedback; investors must file claims by April 13, 2026.

Law firm sues uniQure for allegedly misrepresenting gene therapy trial status and FDA approval timeline, causing stock to surge 250% then fall 49% after FDA reversal.

REGENXBIO faces securities lawsuit for allegedly misleading investors about RGX-111 gene therapy safety concerns. FDA imposed clinical hold after trial participant developed CNS tumor.

Eli Lilly strengthens market position through GLP-1 dominance and strategic acquisitions like Orna Therapeutics, diversifying growth beyond patent cliff risks.